Evidence map›Paper›PMID 25845467›Full record

ArticleCancer2015

Prospective quality-of-life outcomes for low-risk prostate cancer: Active surveillance versus radical prostatectomy.

Claudio Jeldres, Jennifer Cullen, Lauren M Hurwitz, Erika M Wolff, Katherine E Levie, Katherine Odem-Davis, Richard B Johnston, Khanh N Pham, Inger L Rosner, Timothy C Brand and 4 more

Abstract read
In one paragraph

Article in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Claudio JeldresSection of Urology and Renal Transplantation, Virginia Mason, Seattle, Washington.
Jennifer CullenCenter for Prostate Disease Research, Department of Defense, Rockville, Maryland.
Lauren M HurwitzCenter for Prostate Disease Research, Department of Defense, Rockville, Maryland.
Erika M WolffSection of Urology and Renal Transplantation, Virginia Mason, Seattle, Washington.
Katherine E LevieCenter for Prostate Disease Research, Department of Defense, Rockville, Maryland.
Katherine Odem-DavisCenter for Biomedical Statistics, University of Washington, Seattle, Washington.
Richard B JohnstonSection of Urology and Renal Transplantation, Virginia Mason, Seattle, Washington.
Khanh N PhamSection of Urology and Renal Transplantation, Virginia Mason, Seattle, Washington.
Inger L RosnerCenter for Prostate Disease Research, Department of Defense, Rockville, Maryland.
Timothy C BrandCenter for Prostate Disease Research, Department of Defense, Rockville, Maryland.
James O L'EsperanceCenter for Prostate Disease Research, Department of Defense, Rockville, Maryland.
Joseph R SterbisCenter for Prostate Disease Research, Department of Defense, Rockville, Maryland.
Ruth EtzioniDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Christopher R PorterSection of Urology and Renal Transplantation, Virginia Mason, Seattle, Washington.

Funding

Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1TR000423
6 · The paper itself

Abstract

backgroundFor patients with low-risk prostate cancer (PCa), active surveillance (AS) may produce oncologic outcomes comparable to those achieved with radical prostatectomy (RP). Health-related quality-of-life (HRQoL) outcomes are important to consider, yet few studies have examined HRQoL among patients with PCa who were managed with AS. In this study, the authors compared longitudinal HRQoL in a prospective, racially diverse, and contemporary cohort of patients who underwent RP or AS for low-risk PCa.

methodsBeginning in 2007, HRQoL data from validated questionnaires (the Expanded Prostate Cancer Index Composite and the 36-item RAND Medical Outcomes Study short-form survey) were collected by the Center for Prostate Disease Research in a multicenter national database. Patients aged ≤75 years who were diagnosed with low-risk PCa and elected RP or AS for initial disease management were followed for 3 years. Mean scores were estimated using generalized estimating equations adjusting for baseline HRQoL, demographic characteristics, and clinical patient characteristics.

resultsOf the patients with low-risk PCa, 228 underwent RP, and 77 underwent AS. Multivariable analysis revealed that patients in the RP group had significantly worse sexual function, sexual bother, and urinary function at all time points compared with patients in the AS group. Differences in mental health between groups were below the threshold for clinical significance at 1 year.

conclusionsIn this study, no differences in mental health outcomes were observed, but urinary and sexual HRQoL were worse for patients who underwent RP compared with those who underwent AS for up to 3 years. These data offer support for the management of low-risk PCa with AS as a means for postponing the morbidity associated with RP without concomitant declines in mental health.

Indexed as

Mental HealthProstatectomyQuality of LifeWatchful WaitingAgedHealth StatusHumansMaleMiddle AgedPopulation SurveillanceProspective StudiesProstatic NeoplasmsSurveys and Questionnairesactive surveillanceprostate cancerquality of liferadical prostatectomysurvivorship

Identifiers

PMID25845467
PMCPMC4490040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.